Previous Close | 5.20 |
Open | 5.25 |
Bid | 5.00 |
Ask | 5.20 |
Strike | 70.00 |
Expire Date | 2025-01-17 |
Day's Range | 5.20 - 5.25 |
Contract Range | N/A |
Volume | |
Open Interest | 2.79k |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.